A research group from the University of Texas MD Anderson Cancer Center in the United States just reported in the Journal of National Cancer Institute that the addition of two kinds of bloodborne proteins associated with the migration of cancer cells increases the ability of current biomarkers to predicting in early detection of pancreatic cancer. More research using recombinant human proteins should be conducted.

"When used with the current gold standard biomarker CA 19-9, the addition of these two biomarkers provides a significant improvement in statistics for all early cancers and other subpopulations," said Ann Killary, professor of molecular pathology.

Although CA 19-9 is the only biomarker approved by the FDA for the treatment of the disease, antigen markers produced by pancreatic cancer have low positive predictions for the identification of early disease.

In the early stages of pancreatic cancer, patients can be successfully treated by surgery, but surgical treatment is no longer effective when patients develop locally advanced disease (stage III) or have spread to other organs of cancer (stage IV). Therefore, the early diagnosis of pancreatic cancer is crucial.

Killary and colleagues earlier discovered a group of genes involved in cancer migration, and then analyzed the genes produced by these genes. These two proteins, called TFPI and tendon protein C, are the strongest biomarker candidates. The team first compared their predictability by comparing their presence in healthy volunteers and patients with predominantly stage IV pancreatic cancer. In this study, effective use of TFPI and tendon protein C isoform TNC-FN IIIC, used in conjunction with CA 19-9, improved performance identification of stage I and II disease from healthy or benign disease control.

Killary said the team is struggling to use the biomarkers of the MD Anderson High Risk Clinic through the MD Anderson's Pancreas Moon Shooting ? program, which part of the agency's Moon Shooting Program ? has been established to accelerate the development based on scientific discovery. Clinic monitoring has been at high risk for pancreatic cancer due to family history or known risk of increasing gene mutations. "In this population, our biomarker group may be useful in early detection," says Killary. By the way, Flarebio provides you with superior recombinant proteins including recombinant TLR2 at competitive prices.